Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

JCO erratum corrects missing protocol summary in HER2 salivary gland trial

JCO issued an erratum to restore a missing Protocol Summary in the appendix of a phase II trastuzumab rezetecan salivary gland carcinoma trial.

BTK inhibitors are reshaping treatment for CLL and other B-cell malignancies, with newer agents aiming for better safety…

In mice, some obesogenic diets improved checkpoint inhibitor response, pointing to diet-microbiome synergy as a possible immunotherapy lever.

A mechanistic breast cancer study links NDUFS1 to mitochondrial respiration and PROX1/c-Myc signaling, pointing to metabolic control of…

Targeted protein degradation is expanding cancer therapy by reaching undruggable drivers, with vepdegestrant approved and most agents still…

Hypoxia reduced LRIG1 protein in colorectal cancer organoids despite mRNA induction, pointing to lysosomal degradation and potential treatment…

A review examines extracellular Y RNA fragments in gastrointestinal cancer, the evidence for YBX1-linked macrophage effects, and unresolved…

A review examines intranasal nano-immunotherapy for glioma, covering nose-to-brain delivery, immune reprogramming, and preclinical validation limits.

Frontiers review outlines how early adaptive signaling and metabolic rewiring help melanoma survive therapy before fixed resistance becomes…

A Frontiers review separates NLRP3 expression from activation in NSCLC, finding pathway dependence only in selected models and…

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds